12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients living in Scotland will now have access to Orkambi (lumacaftor/ivacaftor) and Symveki (tezacaftor/ivacaftor).

The drugs have been approved in combination with ivacaftor, following the signing of an access agreement.

The company also confirmed that as part of the five-year agreement, it has also committed to collecting real world data on these medicines that will support any future submissions to the committee.

Read Pharma Times article